AbbVie is ending development of an IL-1 asset as a monotherapy in ulcerative colitis (UC) after a phase 2 study revealed insufficient efficacy results. “An interim analysis was recently completed on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback